Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 422

Similar articles for PubMed (Select 16387546)

1.

Is combination antiviral therapy for CMV superior to monotherapy?

Drew WL.

J Clin Virol. 2006 Apr;35(4):485-8. Epub 2006 Jan 18. Review.

PMID:
16387546
2.

Cytomegalovirus Treatment.

Tan BH.

Curr Treat Options Infect Dis. 2014;6(3):256-270. Review.

3.

Leflunomide: a treatment option for ganciclovir-resistant cytomegalovirus infection after renal transplantation.

Andrassy J, Illner WD, Rentsch M, Jaeger G, Jauch KW, Fischereder M.

NDT Plus. 2009 Apr;2(2):149-51. doi: 10.1093/ndtplus/sfp004.

4.

Analysis of ganciclovir-resistant human herpesvirus 6B clinical isolates using quenching probe PCR methodology.

Hiramatsu H, Suzuki R, Yamada S, Ihira M, Isegawa Y, Kawamura Y, Matsuoka E, Miura H, Yoshikawa T.

Antimicrob Agents Chemother. 2015 May;59(5):2618-24. doi: 10.1128/AAC.04692-14. Epub 2015 Feb 17.

PMID:
25691643
5.

Safety of alternative antiviral agents for neonatal herpes simplex virus encephalitis and disseminated infection.

Wang Y, Smith KP.

J Pediatr Pharmacol Ther. 2014 Apr;19(2):72-82. doi: 10.5863/1551-6776-19.2.72. Review.

6.

When does 2 plus 2 equal 5? A review of antimicrobial synergy testing.

Doern CD.

J Clin Microbiol. 2014 Dec;52(12):4124-8. doi: 10.1128/JCM.01121-14. Epub 2014 Jun 11.

7.

Preparation, characterization and in vitro antiviral activity evaluation of foscarnet-chitosan nanoparticles.

Russo E, Gaglianone N, Baldassari S, Parodi B, Cafaggi S, Zibana C, Donalisio M, Cagno V, Lembo D, Caviglioli G.

Colloids Surf B Biointerfaces. 2014 Jun 1;118:117-25. doi: 10.1016/j.colsurfb.2014.03.037. Epub 2014 Mar 29.

PMID:
24742953
8.

Leflunomide as part of the treatment for multidrug-resistant cytomegalovirus disease after lung transplantation: case report and review of the literature.

Verkaik NJ, Hoek RA, van Bergeijk H, van Hal PT, Schipper ME, Pas SD, Beersma MF, Boucher CA, Jedema I, Falkenburg F, Hoogsteden HC, van den Blink B, Murk JL.

Transpl Infect Dis. 2013 Dec;15(6):E243-9. doi: 10.1111/tid.12156. Epub 2013 Oct 23. Review.

PMID:
24298985
9.

In vitro combination of anti-cytomegalovirus compounds acting through different targets: role of the slope parameter and insights into mechanisms of Action.

Cai H, Kapoor A, He R, Venkatadri R, Forman M, Posner GH, Arav-Boger R.

Antimicrob Agents Chemother. 2014;58(2):986-94. doi: 10.1128/AAC.01972-13. Epub 2013 Nov 25.

10.

Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens.

Minces LR, Nguyen MH, Mitsani D, Shields RK, Kwak EJ, Silveira FP, Abdel-Massih R, Pilewski JM, Crespo MM, Bermudez C, Bhama JK, Toyoda Y, Clancy CJ.

Antimicrob Agents Chemother. 2014;58(1):128-35. doi: 10.1128/AAC.00561-13. Epub 2013 Oct 21.

11.

Effect of ganciclovir for the treatment of severe cytomegalovirus-associated pneumonia in children without a specific immunocompromised state.

Doan TT, Phung TT, Pham HV, Pham SH, Nguyen LT.

BMC Infect Dis. 2013 Sep 9;13:424. doi: 10.1186/1471-2334-13-424.

12.

Ribonucleotide reductase inhibitors hydroxyurea, didox, and trimidox inhibit human cytomegalovirus replication in vitro and synergize with ganciclovir.

Bhave S, Elford H, McVoy MA.

Antiviral Res. 2013 Oct;100(1):151-8. doi: 10.1016/j.antiviral.2013.07.016. Epub 2013 Aug 6.

13.

Foscarnet in the management of cytomegalovirus infections in hematopoietic stem cell transplant patients.

Bacigalupo A, Boyd A, Slipper J, Curtis J, Clissold S.

Expert Rev Anti Infect Ther. 2012 Nov;10(11):1249-64. doi: 10.1586/eri.12.115. Epub 2012 Nov 21. Review.

PMID:
23167560
14.

The role of therapeutic drug monitoring in the treatment of cytomegalovirus disease in kidney transplantation.

Bedino G, Esposito P, Bosio F, Corradetti V, Valsania T, Rocca C, Pattonieri EF, Gregorini M, Rampino T, Dal Canton A.

Int Urol Nephrol. 2013 Dec;45(6):1809-13. doi: 10.1007/s11255-012-0293-y. Epub 2012 Sep 30.

PMID:
23054314
15.

[Q & A. Enteritis found in a young man].

Nakamura K.

Nihon Shokakibyo Gakkai Zasshi. 2011 Nov;108(11):1924-5,1928-9. Japanese. No abstract available.

PMID:
23038850
16.

Pharmacokinetics, pharmacodynamics and clinical use of valganciclovir in newborns with symptomatic congenital cytomegalovirus infection.

Stronati M, Lombardi G, Garofoli F, Villani P, Regazzi M.

Curr Drug Metab. 2013 Feb;14(2):208-15. Review.

PMID:
22935067
17.

[Different dosages Ganciclovir treatment of symptomatic congenital cytomegalovirus infection in neonatal].

Hong-Bin Z, Feng-Xian Z, Cai-Ping G.

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2012 Feb;26(1):57-9. Chinese.

PMID:
22919757
18.

Repopulation of ganciclovir-resistant cytomegalovirus by wild-type virus.

Drew WL, Liu C.

Clin Transplant. 2012 Nov-Dec;26(6):949-52. doi: 10.1111/j.1399-0012.2012.01681.x. Epub 2012 Jul 9.

PMID:
22774759
19.

Crystal precipitation and granulomatous inflammation in multiple organs after foscarnet therapy in a lung transplant recipient.

Tischler V, Schuurmans MM, Boehler A, Gaspert A.

J Heart Lung Transplant. 2012 Sep;31(9):1037-40. doi: 10.1016/j.healun.2012.05.008. Epub 2012 Jul 4.

PMID:
22766024
20.

[Anti-cytomegaloviral drugs].

Yasuoka A.

Nihon Rinsho. 2012 Apr;70(4):564-7. Review. Japanese.

PMID:
22568135
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk